Curium, a leading producer of radiopharmaceuticals, and CapVest Partners LLP (CapVest), a global investment firm, have announced the recapitalization of Curium via a new Continuation Vehicle (CV). The CV values Curium at circa $7 billion, representing the largest transaction in nuclear medicine globally. The transaction elicited wide support from existing and new institutional investors across the US, Europe, the Middle East and APAC. This includes lead investors ICG, TPG GP Solutions, CVC Secondary Partners and other investors such as Goldman Sachs Alternatives, Lunate, Pantheon, and Ardian. Curium also secured a minority investment from TPG Life Sciences Innovations.
Read the full article: CapVest Recapitalizes Curium to Accelerate Its Growth Strategy, Marking the Largest Transaction in Nuclear Medicine Globally //
Source: https://www.globenewswire.com/news-release/2025/11/20/3191781/0/en/CapVest-recapitalizes-Curium-to-accelerate-its-growth-strategy-marking-the-largest-transaction-in-nuclear-medicine-globally.html